Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight ...
Semaglutide led to significant reductions in body weight, blood pressure, cholesterol, and HbA1c, but improvements were smaller than in clinical trials. Patients without diabetes experienced greater ...
Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...
A groundbreaking international trial has found that semaglutide, a drug best known for treating diabetes and obesity, can also reverse a dangerous liver disease called MASH in nearly two-thirds of ...
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the ...
Adjunctive use of the GLP-1 receptor agonist semaglutide was associated with greater glycemic control and better weight outcomes in patients with schizophrenia spectrum disorders, new research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results